Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
18665826

DOI
10.1111/j.1751-553X.2007.00955.x

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols /adverse effects; Cost-Benefit Analysis; Cross-Over Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor /administration & dosage /economics; Humans; Lymphoma, Non-Hodgkin /drug therapy /economics; Male; Middle Aged; Neutropenia /drug therapy /etiology; Recombinant Proteins /administration & dosage /economics

AccessionNumber
22008102500

Date bibliographic record published
24/06/2009